Molecular Mechanisms of Bone Metastasis and Therapeutic Implications

Clinical Orthopaedics and Related Research

Volumn 415, Issue SUPPL., 2003, Pages

  O'Keefe, Regis J ^a   Guise, Theresa A ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BONE MORPHOGENETIC PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; ENDOTHELIN; GROWTH FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLATELET DERIVED GROWTH FACTOR; TRANSCRIPTION FACTOR; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANTISENSE TECHNOLOGY; BONE METASTASIS; CANCER RESEARCH; CANCER THERAPY; CELL MIGRATION; CONFERENCE PAPER; DRUG DEVELOPMENT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE THERAPY; HUMAN; IMMUNOCOMPETENT CELL; MOLECULAR BIOLOGY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RECOMBINANT DNA TECHNOLOGY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR VASCULARIZATION;

EID: 0142157084     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000093847.72468.2f     Document Type: Conference Paper

References (52)

1. Andela VB, Gingold BI, Souza MD, et al: Clinical relevance of increased retinoid and cAMP transcriptional programs in tumor cells rendered non-malignant by dominant negative inhibition of NFkappaB. Cancer Lett 194:37-43, 2003.
2. Andela VB, Rosenblatt JD, Schwarz EM, et al: Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis. Clin Orthop 397:228-239, 2002.
3. Andela VB, Schwarz EM, Puzas JE, O'Keefe RJ, Rosier RN: Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res 60:6557-6562, 2000.
4. Andela VB, Sheu TJ, Puzas JE, et al: Malignant reversion of a human osteosarcoma cell line, Saos-2, by inhibition of NFkappaB. Biochem Biophys Res Commun 297:237-241, 2002.
5. Brandstrom H, Jonsson KB, Ohlsson C, et al: Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem Biophys Res Commun 247:338-341, 1998.
6. Brandstrom H, Jonsson KB, Vidal O, et al: Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 248:454-457, 1998.
7. Clohisy DR, Mantyh PW: Bone cancer pain. Cancer 97:866-873, 2003.
8. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ: CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 34:162-168, 1998.
9. Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826, 2001.
10. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998, 2002.
11. Funaki H, Nishimura G, Harada S, et al: Expression of vascular endothelial growth factor d is associated with lymph node metastasis in human colorectal carcinoma. Oncology 64:416-422, 2003.
12. Garcia-Lora A, Algarra I, Garrido F: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195:346-355, 2003.
13. Goltzman D: Mechanisms of the development of osteoblastic metastases. Cancer 80:1581-1587, 1997.
14. Guise TA: Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-2898, 2000.
15. Guise TA, Yin JJ, Mohammad KS: Role of endothelin-1 in osteoblastic bone metastases. Cancer 97:779-784, 2003.
16. Hanash S: Disease proteomics. Nature 422:226-232, 2003.
17. Hillner BE, Ingle JN, Berenson JR, et al: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer: American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18:1378-1391, 2000.
18. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250:776-781, 1998.
19. Hofbauer LC, Khosla S, Dunstan CR, et al: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12, 2000.
20. Hofbauer LC, Lacey DL, Dunstan CR, et al: Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255-259, 1999.
21. Honore P, Rogers SD, Schwei MJ, et al: Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98:585-598, 2000.
22. Honore P, Schwei J, Rogers SD, et al: Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res 129:389-397, 2000.
23. Kakonen SM, Selander KS, Chirgwin JM, et al: Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277:24571-24578, 2002.
24. Koeneman KS, Yeung F, Chung LW: Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39:246-261, 1999.
25. Lam J, Takeshita S, Barker JE. et al: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481-1488, 2000.
26. Luger NM, Sabino MA, Schwei MJ, et al: Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 99:397-406, 2002.
27. Mach DB, Rogers SD, Sabino MC, et al: Origins of skeletal pain: Sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155-166, 2002.
28. Maisano R, Pergolizzi S, Cascinu S: Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol 40:239-250, 2001.
29. Major PP, Lipton A, Berenson J, Hortobagyi G: Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 88:6-14, 2000.
30. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E: Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:18-24, 2001.
31. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP: Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201-209, 2002.
32. Muller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56, 2001.
33. Mundy G: Preclinical models of bone metastases. Semin Oncol 28:2-8, 2001.
34. Nakopoulou L, Tsirmpa I, Alexandrou P, et al: MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 77:145-155, 2003.
35. Nosaka K, Miyamoto T, Sakai T, et al: Mechanism of hypercalcemia in adult T-cell leukemia: Over-expression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 99:634-640, 2002.
36. O'Keefe RJ, Schwarz EM, Boyce BF: Bone metastases: An update on mechanisms of bone resorption and therapeutic strategies. Curr Opin Orthop 11:353, 2000.
37. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442, 2002.
38. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA: The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: Implications for the development of metastatic disease. Endocrinology 138:1145-1150, 1997.
39. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH: Animal models of bone metastasis. Cancer 97:748-757, 2003.
40. Shalhoub V, Faust J, Boyle WJ, et al: Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem 72:251-261, 1999.
41. Sotiriou C, Lacroix M, Lespagnard L, et al: Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett 169:87-96, 2001.
42. Szczepek AJ, Belch AR, Pilarski LM: Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: Potential for autocrine and paracrine networks. Exp Hematol 29:1076-1081, 2001.
43. Tester AM, Ruangpani N, Anderso RL, Thompson EW: MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis 18:553-560, 2000.
44. Tumber A, Morgan HM, Meikle MC, Hill PA: Human breast-cancer cells stimulate the fusion, migration and resorptive activity of osteoclasts in bone explants. Int J Cancer 91:665-672, 2001.
45. Udagawa N, Takahashi N, Jimi E, et al: Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand. Bone 25:517-523, 1999.
46. Uehara H, Kim SJ, Karashima T, et al: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95:458-470, 2003.
47. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002.
48. Verheul HM, Pinedo HM: The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer 1(Suppl 1):S80-84, 2000.
49. Yasuda H, Shima N, Nakagawa N, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TANCE/RANKL. Proc Natl Acad Sci 95:3597-3602, 1998.
50. Yin JJ, Selander K, Chirgwin JM, et al: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206, 1999.
51. Yu Q, Stamenkovic I: Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13:35-48, 1999.
52. Zheng DQ, Woodard AS, Fomaro M, Tallini G, Languino LR: Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59:1655-1664, 1999.